Skip to main content

ASK THE EXPERT: First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

The Lynx Group: 2022 Ask The Expert M Choi.pdf
Please Click the Issue to Download


This resource provides insights from a medical oncologist who specializes in gastric cancer and esophageal cancer. Here you will find information on the expanded analyses of efficacy and safety at a 24-month follow-up from Checkmate 649, a multicenter, randomized, phase 3, open-label study that evaluated OPDIVO plus capecitabine and oxaliplatin (CapeOX) or OPDIVO plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX) compared with CapeOX or FOLFOX alone as first-line therapy in patients with previously untreated, unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Download to Continue Reading